Cointime

Medisix Therapeutics

company

About

Medisix Therapeutics is a provider of immune engineering company developing novel cellular therapies.

  • Singapore,Central Region,Singapore
  • 1 - 10

Highlights

Total Funding Amount
$20M
Funding Rounds
1
Investors
3
Employee Profiles
1

Details

Last Funding Type
Series A
Last Funding Money Raised
$20M
Industries
Biotechnology,Chemical Engineering,Life Science
Founded date
Jan 1, 2018
Number Of Employee
1 - 10
Operating Status
Active
Legal Name
MediSix Therapeutics, Inc.

Medisix Therapeutics is a Singapore-based immune engineering company developing novel cellular therapies to address T cell malignancies. Their technology platform originates from world expert in translational immunology, Professor Dario Campana, MD, PhD, a physician scientist who pioneered chimeric antigen receptor T cell (CAR-T) biology. Their programs utilize proprietary immune engineering approaches that enable T cell leukemias and lymphomas to be targeted with cell therapy.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$20M
Medisix Therapeutics has raised a total of $20M in funding over 2 rounds. Their latest funding was raised on May 15, 2018 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 15, 2018 Series A $20M 3 Lightstone Ventures — Detail

Investors

Number of Lead Investors
Number of Investors
1
3
Medisix Therapeutics is funded by 3 investors. Lightstone Ventures and OUP (Osage University Partners) are the most recent investors.
Investor Name Lead Investor Funding Round
Lightstone Ventures Yes Series A
OUP (Osage University Partners) — Series A
Temasek Holdings — Series A

Employee Profiles

Number of Employee Profiles
1
Medisix Therapeutics has 1 current employee profiles, including Executive Dario Campana
Dario Campana
Executive
Cointime
Content
Company